Skip to main content
Premium Trial:

Request an Annual Quote

Proteros Inks Deal to Provide Access to UC DCC's Screening Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein structure analysis firm Proteros today announced a deal with the University of Cincinnati, Drug Discovery Center to provide biotechnology and drug firms access to UC DDC's ultra-high throughput and high-content screening platform along with a library of more than 340,000 drug-like compounds.

Proteros, based in Martinsried, Germany, will serve as a single point of contact and be responsible for all client interactions and project management.

Financial and other terms of the deal were not disclosed.

"This powerful academic-industry collaboration in translational research combines leading capabilities at the UC DDC with Proteros' proven technical and commercial expertise in providing discovery services and will continue to expand our base of pharmaceutical and biotechnology clients," Ruben Papoian, director of UC DDC, said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.